GlobeNewsWire
19 Aug 2026, 17:54 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA's briefing documents revealed that Capricor Therapeutics submitted a final statistical analysis plan (SAP) for its Dermamiocel BLA that was not previously discussed or agreed upon with the agency. — Lack of agreement with the FDA on a statistical analysis plan significantly increases the risk of a BLA rejection or a request for additional trials, which is a primary value driver for biotech firms.
-0.80A securities class action lawsuit has been filed against Capricor Therapeutics alleging misconduct between December 17, 2025, and July 26, 2026. — Litigation creates financial liability and management distraction, though the underlying regulatory failure is the primary catalyst for the price drop.
-0.40Capricor's stock price experienced a single-day decline of 64% on July 27, 2026, following the release of the FDA briefing documents. — While this confirms the market's negative reaction, it is a lagging indicator of the fundamental regulatory risk already established.
-0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company is facing a class action lawsuit following a 64% stock price drop due to FDA briefing document issues.
The company is mentioned in the context of a securities class action deadline.
The company is mentioned in the context of a securities class action deadline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
7h ago
